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Abstract
Aims: To compare the risk of vascular disease, HbA1c and weight change, between first prescribed insulins in people with
type 2 diabetes.
Methods: People included in THIN United Kingdom primary care record database who began insulin (2000–2007) after poor
control on oral glucose-lowering agents (OGLD) were grouped by the number of OGLDs in their treatment regimen
immediately before starting insulin (n = 3,485). Within OGLD group, Cox regression compared macrovascular (all-cause
mortality, myocardial infarction, acute coronary syndrome and stroke) and microvascular disease (peripheral neuropathy,
nephropathy, and retinopathy) between insulin type (basal, pre-mix or Neutral Protamine Hagedorn, NPH) while ANCOVAs
compared haemoglobin A1c (HbA1c) and weight change.
Results: Mean follow-up was 3.6 years. Rates of incident macrovascular events were similar when basal insulin was
compared to pre-mix or NPH, adjusted hazard ratio versus basal: pre-mix 1.08 (95% CI 0.73, 1.59); NPH 1.00 (0.63, 1.58) after
two OGLDs, and pre-mix 0.97 (0.46, 2.02); NPH 0.77 (0.32, 1.86) after three OGLDs. An increased risk of microvascular disease
in NPH versus basal after 3 OGLDs, adjusted hazard ratio1.87 (1.04, 3.36), was not seen after two agents or in comparisons of
basal and pre-mix. At one year, after two OGLDs, weight increase was less with basal compared with pre-mix. After three
OGLDs, mean HbA1c had reduced less in basal versus pre-mix or NPH at 6–8 and at 9–11 months, and versus pre-mix at 12–
14 months.
Conclusion: We found no difference in the risk of macrovascular events between first insulins in the medium term when
started during poor glycaemia control. The increased risk of microvascular events with NPH warrants further study. In certain
groups, first use of basal insulin was associated with less gain in weight and decrease in HbA1c compared to other insulins.
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Introduction
A short-term aim of type 2 diabetes management is good
glycaemic control with a longer-term objective of reducing
complications. People with known type 2 diabetes have a two-
to four-fold increased risk of ischaemic heart disease (IHD) and an
increased risk of microvascular disease [1]. Initial pharmaceutical
treatment is usually with an oral therapy. However, a steady
decline in islet b-cell function usually results in progressive
hyperglycaemia so a stepwise escalation in the number of OGLDs
prescribed is frequently required to maintain glycaemic control.
Eventually, many people require insulin to maintain glycaemic
control as insulin secretion decreases [2]. The choice when
beginning insulin treatment is usually between human NPH
insulin (NPH) injected once or twice daily, a long-acting basal
insulin analogue (basal) or a pre-mix preparation. Current United
Kingdom (UK) National Institute for Health and Clinical
Excellence guidance recommends beginning with NPH but to
consider long-acting analogues or pre-mixed insulin formulations
under specified circumstances [3].
There is little published data from routine care as to the effect of
the choice of insulin on HbA1c levels, body weight change and
subsequent vascular disease. Clinical trials in type 2 diabetes have
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reported less weight increase and less reduction in HbA1c but
fewer hypoglycaemic episodes during treatment with basal insulin
[4,5]. No evidence of a greater risk of the development or
progression of diabetic retinopathy between treatments after five
years was reported in a trial of insulin glargine versus NPH insulin
[6]. The ORIGIN study reported that over 6 years, insulin
glargine did not increase the risk of cardiovascular outcomes
compared to standard care in those with cardiovascular risk factors
plus impaired fasting glucose, impaired glucose tolerance, or type
2 diabetes [7]. The aim of the present study was to investigate
whether, in routine clinical practice, the occurrence of vascular
outcomes, and the change in HbA1c and body weight, was
different depending on which insulin type was prescribed first.
Methods
Ethics Statement
The manuscript describes a non-interventional study so in-
formed consent was not required. The protocol was approved by
the Cambridgeshire 4 Research Ethics Committee (UK).
Source Population
All data came from The Health Information Network (THIN),
an observational database containing information collected in
computerized primary care practices throughout the UK (http://
www.thin-uk.com/) [8]. Demographic and administrative data,
primary care diagnoses and prescription treatments are routinely
recorded against date in individual patient records. Details of
referrals, secondary care diagnoses and deaths are also captured
due to the structure of the UK health service. The UK has
a publicly funded healthcare system which is free to UK residents.
Within this system patients are registered with one general
practitioner who is involved in primary healthcare, specialist
referrals, and hospital admissions. Consequently the electronic
primary care record is a centralised source of information on these
events. Major health events from before computerization are
added retrospectively. Data on preventive medicine are recorded
including details of any annual diabetes review. Medical events are
automatically coded at entry using the Read coding system [9].
The source population comprised 202 456 people with a record of
diabetes from 381 practices which received laboratory results
electronically.
Cohort Formation and Treatment Definition
People (n = 105 845) identified were those who had received at
least one prescription for an OGLD after 1st January 2000 but had
no prior or current prescription for insulin. A sub-group, who
began insulin treatment between 1st January 2000 and the most
recent data collection (up to 30th November 2008), were selected.
Beginning insulin was defined as more than one insulin pre-
scription as short-term insulin is commonly used during periods of
ill health and we were interested in the effects of long-term
treatment. In that population, the duration of each OGLD type
(metformin, gliclazide, pioglitazone, etc.) was calculated from 1st
January 2000 up to beginning insulin. The number of OGLD
types still prescribed immediately prior to starting insulin (baseline)
was counted. It was assumed that a treatment stopped as a new
drug was started if there were no further prescriptions for the first
OGLD within a time period which was double that of the duration
of the last prescription for this drug. OGLD duration was
calculated from the number of items and dosage prescribed. When
insufficient dosage information was recorded for the calculation of
duration the most common dose for that form and strength of the
OGLD was used.
Those who started insulin were initially grouped into nine
cohorts depending on the combination of the number of baseline
therapies (one, two or three oral agents) and whether basal, NPH
or pre-mix was started. The number of baseline therapies was used
in the groupings as the stage at which insulin is started can be
related to diabetes duration, severity and concomitant disease.
Patients initiating other insulins or combinations of insulins and
those restarting insulin therapy were not included. Consequently
analyses were always completed for mutually exclusive groups.
The date of the first insulin prescription was taken as the index
date. People with more than one year of electronic record pre- or
post-index date, aged between 18 and 80 were included. The one
year pre-insulin period gave sufficient medical record length to
identify new insulin users and those with a history of the study
outcomes. People with no interpretable HbA1c record in the three
months prior to index date, the most recent HbA1c ,7.5%
(58 mmol/mol) or no body weight record in the previous 15
months, were excluded. The HbA1c criteria were chosen to ensure
that only people in poor blood glucose control were included.
Comparisons of those who started insulin from one baseline
OGLD are not reported. This was because commencing insulin
after one agent was uncommon with few vascular events reported
and a parallel study comparing OGLD and insulin found that
patients who initiated insulin treatment from a regimen of one oral
therapy differed from other patients in terms of both medical
history and data recording [10].
Outcomes
The primary cardiovascular endpoint was a composite of all-
cause mortality, myocardial infarction, acute coronary syndrome,
or stroke. Angina and coronary procedures were added to the
primary cardiovascular endpoint in sensitivity analyses. The
microvascular endpoint was a composite of peripheral neuropathy,
diabetic nephropathy, and retinopathy. The first event was taken
for the composite endpoints. Patients with events prior to the index
date were excluded from the relevant analysis. Amputations were
identified but in insufficient numbers to perform comparative
statistical analysis. Change in HbA1c and body weight in the year
after index date were secondary outcomes.
Baseline Covariates
The following potential confounding baseline variables were
extracted: age, sex, recorded duration of diabetes, most recent
HbA1c, year of starting insulin, OGLD and cardiovascular
therapies, history of vascular disease and its risk factors. OGLD
(sulfonylurea, metformin, thiazolidinediones, combinations of
these or other) and cardiovascular therapies (British National
Formulary categories 2.2–2.6 [11]) were defined as a prescription
in the 16 weeks up to and including the index date. History of
vascular disease included IHD (MI, angina, coronary revascular-
isation, or IHD), cerebrovascular disease (any stroke, transient
ischaemic attack or cerebral insufficiency/ischaemia), peripheral
arterial disease, heart failure, hypertension, or microvascular
complications (as above). Other cardiovascular risk factors
ascertained included: hyperlipidaemia (as a diagnosis, cholesterol:
high density lipoprotein ratio .4.5 or total serum cholesterol
.5.2 mmol/l); body mass index (BMI); smoking status; estimated
glomerular filtration rate in the previous year [12,13], micro-
albuminuria defined as a diagnosis or an abnormal urine albumin
concentration or albumin: creatinine ratio.
Analyses
The baseline characteristics of the total cohorts (before
exclusions for prevalent disease) were described. Comparisons
Vascular Events after First Insulins
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were made for basal versus NPH and basal versus pre-mix with the
same number of baseline OGLDs. Follow-up started on the date of
the first insulin prescription plus 12 months and was censored on
the date of the first outcome for that analysis, transfer out of the
practice or last data collection. Outcomes in the first 12 months of
treatment were not included in the analysis as the insulin was
unlikely to have an effect on vascular outcomes in a short time
scale. All events from the year after insulin was started were
included, regardless of further treatment changes or inclusion in
additional cohorts, in a similar manner to intention to treat
analysis in randomised clinical trials. This design was chosen
because of the time for the effects of poor glycaemic control on
vascular outcomes to become evident and because censoring when
a patient joined a second cohort could have introduced bias with
shorter follow-up in patients with worse control.
Adjusted hazard ratios of the association between our treatment
categories and incident (first event) microvascular and macro-
vascular outcomes were compared using Cox regression models.
People with a pre-insulin history of any disease within that
composite outcome, or with outcomes in the first year or who
transferred out during this time, did not contribute to that analysis.
Each baseline covariate was included as a variable in the model for
the primary macrovascular outcomes with the microvascular
conditions included separately and year of first insulin treated as
a continuous variable. Angina and coronary procedures were
removed as covariates when these were added to the composite
outcomes in sensitivity analyses. All baseline variables except
microvascular disease itself were included in the microvascular
disease models.
The association of treatment category with body weight change
and HbA1c in the year after insulin initiation were investigated
with the treatment groups compared as outlined above adjusting
for baseline age, sex, duration of diabetes, year of escalation, BMI,
HbA1c, and oral treatment regimen. The changes in weight from
baseline to approximately one year (10–15 months) and HbA1c
over three month intervals (4–14 months) were compared using
ANCOVA least squares means. All data analysis was performed
using SAS software (version 9.1, Cary, NC, USA).
Results
There were 8149 people who started insulin after two or three
OGLDs of whom 2432 had less than one year history or follow-up;
3043 had no interpretable baseline HbA1c record over 7.5%
(58 mmol/mol) available in the 90 days before insulin was started;
558 had no baseline weight reading and 623 were ,18 or .80
years of age. After all exclusions, 2537 people began insulin after
two OGLDs and 890 after three. NPH was the least common first
insulin being prescribed to less than 20% of people in any group
(Table 1).The mean total follow-up period was 3.6 years across
groups. Baseline therapies were similar across insulin types with
the majority of people on two baseline therapies being prescribed
metformin and a sulfonylurea with a thiazolidinedione added as
the third agent (Table 2).
The risk of microvascular disease was greater in the NPH group
compared to basal analogue insulin after three oral agents, but not
after two OGLDs, adjusted hazard ratios 1.87 (95% confidence
interval 1.04, 3.36) and 1.03 (0.73, 1.45) respectively (Table 3). No
difference in microvascular events was seen between basal and
pre-mix after either two or three OGLDs. No statistically
significant difference in the rate of macrovascular events, or
macrovascular events plus angina or coronary revascularisation
were seen after adjustment for baseline characteristics (Table 3).
However, the adjusted hazard ratio for the comparison of
macrovascular disease plus angina in basal analogue versus premix
after two OGLDs was 1.50 with a lower confidence interval of
0.99.
In all cohorts and at all time periods there was a decrease in
HbA1c after beginning insulin but the mean HbA1c remained
above the target of 7.0–7.5% (53–58 mmol/mol) in all groups
(Table 4). There was no difference in HbA1c change between any
groups who began insulin after two oral agents. In those who had
three baseline therapies there was a smaller decrease in HbA1c
when basal analogue was begun compared to both pre-mix (6 to
14 months after index date) and NPH (6 to 11 months after index
date).
Body weight increased after commencing insulin in all cohorts
(Table 4). The increase in weight was least in the basal analogue
cohorts, but after adjustment for baseline variables the difference
was significant only when the basal treatment group was compared
to pre-mix in those who had been on two oral agents.
Discussion
Our data suggest that, in routine practice, people with type 2
diabetes and initially poor glycaemic control have a similar risk of
major macrovascular events (MI, acute coronary syndrome, stroke
or death) in the medium term regardless of what type of insulin is
started. The mean follow-up was 3.6 years although events in the
first year were not included. Fewer patients started insulin after
three oral agents resulting in a small number of outcomes and
upper 95% confidence intervals close to two. The sensitivity
analysis comparing macrovascular disease plus angina in premix
insulin versus basal analogue after two OGLDs had a hazard ratio
of 1.49 and a lower 95% confidence interval of 0.99 although the
same comparison after three oral agents did not show a difference
in risk between the insulins with a hazard ratio of 0.76 (95%
confidence interval 0.39, 1.51).
Rates of incident microvascular conditions were similar in the
treatment groups except in the comparison between basal insulin
and NPH after a regimen of three oral agents. The increased rate
after NPH is unlikely to be due to better short-term glycaemic
control as there was no difference in baseline HbA1c levels but
a statistically significant greater improvement in glycaemic control
from 6 to 11 months after starting NPH rather than basal insulin.
A sharp increase in both testing for diabetes complications [14]
and diagnosis of some conditions has been reported after the
introduction of the 2004 UK Quality and Outcomes Framework
which provided incentives for routine surveillance of people with
diabetes. An increased microvascular risk could be due to NPH
being started before 2004 more frequently than was the new basal
insulin. However, inclusion of year of first insulin in the adjusted
analysis should have accounted for this difference. While no
difference in the rate of microvascular disease was found after
escalation from the larger number of patients who started insulin
after two oral agents, there were anticipated differences between
those who started insulin from two rather than three oral agents,
such as similar HbA1c after a shorter duration of diabetes, which
might impact on the development of these complications. This
finding therefore warrants further investigation. Differences in
weight gain and glycaemic control were identified between insulin
groups in the first year of treatment. Starting basal insulin was
associated with less reduction in HbA1c than other insulins after
three oral agents but less weight gain than pre-mix after two oral
agents.
No observational studies or clinical trials were found which
specifically aimed to compare the rate of macrovascular disease
between first insulins. The Treating to Target in Type 2 diabetes
Vascular Events after First Insulins
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(4-T) clinical trial found no significant difference in death rate
between basal, biphasic and prandial insulin regimens over 3
years, but a higher rate of death from cardiovascular disease in the
prandial than the biphasic and basal groups [15]. A five-year trial
of insulin glargine versus NPH insulin treatment in patients with
type 2 diabetes mellitus showed no evidence of a greater risk of the
development or progression of diabetic retinopathy between
treatments [6]. A smaller decrease in HbA1c in basal insulin
versus NPH treated patients was reported in that trial and in the 4-
T study when basal insulin (detemir) was compared to both
biphasic and prandial treatment [4]. HbA1c levels later converged
in the 4-T study after usual addition of other insulins, [15] and in
the Treat to Target study more glargine users eventually achieved
a target of HbA1c #7.0% (53 mmol/mol) without nocturnal
hypoglycaemia [16].
Less weight gain in the basal group in routine care was
consistent with several clinical trials of basal compared to other
insulins [4,17–19]. Lower weight gain with basal insulin is believed
to be a consequence of lesser hyperinsulinaemia in the post-
prandial period, with consequent less hunger as a result of lower
plasma glucose concentration, and perhaps concomitantly less
frequent need for correction of hypoglycaemia with carbohydrates.
We were not able to compare the rates of hypoglycaemic events
between groups or in relation to HbA1 c as primary care records
only capture episodes known to the physician rather than events
treated by family, paramedics or the patient themselves.
Insulin was often started when glycaemic control was very poor,
with mean HbA1c 9.9% (85 mmol/mol) (after exclusion of 8%
with baseline HbA1c ,7.5% (58 mmol/mol)). This mean is higher
than many clinical trials, which often have an upper as well as
lower inclusion limit [4,17,19], demonstrating that trial popula-
tions may not always be representative of routine practice. It is
consistent with the ad-hoc observational CREDIT study con-
ducted in Europe, Canada and Japan [20]. Overall glucose
lowering was good (means 1.0–1.7%) after 12 months and, unlike
interventional studies, could not be biased by selection of patients
or physicians. Nevertheless, because starting HbA1c levels were
high, control to target was not achieved in the majority of people
even after one year.
This study has a number of limitations. While we were able to
adjust for many potential confounding variables, severity of
prevalent vascular disease (such as angina), prior long term
Table 1. Characteristics of the insulin cohorts.
2 oral baseline treatments 3 oral baseline treatments
basal analogue pre-mix NPH basal analogue pre-mix NPH
Total (n) 1033 1063 441 394 336 160
Age: (yr) mean (SD) 61.6 (11.1) 61.1 (11.1)** 61.8 (11.1) 61.0 (10.2) 61.7 (9.9)** 63.9 (10.2)**
Total follow-up (yr) mean (SD) 3.1 (1.2) 4.1 (1.9)** 4.1 (1.8)** 2.7 (1.2) 3.7 (1.8)** 4.0 (1.9)**
Diabetes duration (yr) mean (SD) 7.8 (5.1) 8.4 (6.7)* 7.9 (4.9) 9.6 (6.3) 9.1 (5.8) 9.4 (5.3)
Female n (%) 458 (44.3) 441 (41.5) 207 (46.9) 147 (37.3) 127 (37.8) 62 (44.3)
Escalation 2004–2007 n (%) 924 (89.5) 579 (54.5)** 233 (52.8)** 361 (91.6) 217 (64.6)** 83 (59.3)**
Cholesterol (mmol/l) mean (SD) 6.3 (1.6) 6.3 (1.5) 6.1 (1.7)* 6.4 (1.6) 6.5 (2.9) 6.3 (1.3)
BMI (kg/m2) mean (SD) 31.1 (6.4) 30.0 (6.0)** 30.9 (6.8) 31.5 (6.9) 30.3 (6.4)* 30.4 (5.5)
Smoker n (%) 186 (18.0) 194 (18.3) 84 (19.1) 59 (15.0) 61 (18.2) 21 (15.0)
eGFR (ml/min/1.73 m2) n (%):
,30 8 (0.8) 17 (1.7)* 3 (0.7) 3 (0.8) 5 (1.6) 1 (0.7)
30–60 220 (21.6) 253 (24.7) 78 (18.3) 73 (18.9) 69 (21.6) 33 (24.4)
History of (n (%):
Macrovascular diseasea 142 (13.8) 173 (16.3) 66 (15.0) 48 (12.2) 48 (14.3) 17 (12.1)
Microvascular diseaseb 251 (24.3) 281 (26.4) 113 (25.6) 122 (31.0) 110 (32.7) 35 (25.0)
Cardiovascular drug use 957 (92.6) 904 (85.0)** 384 (87.1)** 378 (95.9) 306 (91.1)** 124 (88.6)**
Coronary revascularisation 71 (6.9) 69 (6.5) 29 (6.6) 29 (7.4) 23 (6.9) 10 (7.1)
Heart failure 52 (5.0) 72 (6.8) 26 (5.9) 16 (4.1) 23 (6.9) 6 (4.3)
Angina 207 (20.0) 227 (21.4) 93 (21.1) 69 (17.5) 67 (19.9) 23 (16.4)
Cerebral insufficiency 50 (4.8) 45 (4.2) 15 (3.4) 11 (2.8) 19 (5.7) 6 (4.3)
Hypertension 579 (56.1) 613 (57.7) 236 (53.5) 224 (56.9) 187 (55.7) 76 (54.3)
PAD 71 (6.9) 78 (7.3) 24 (5.4) 22 (5.6) 21 (6.3) 5 (3.6)
Amputation 10 (1.0) 10 (0.9) 5 (1.1) 2 (0.5) 8 (2.4) 1 (0.7)
Microalbuminuria 102 (9.9) 85 (8.0) 42 (9.5) 55 (14.0) 32 (9.5) 14 (10.0)
Hyperlipidaemia 691 (66.9) 682 (64.2) 282 (64.0) 283 (71.8) 225 (67.0) 92 (65.7)
eGFR estimated glomerular filtration rate, PAD peripheral arterial disease.
aComposite of MI, acute coronary syndrome or stroke;
bComposite of neuropathy, nephropathy, and retinopathy;
*p,0.05
**p,0.01, compared to basal insulin, chi-squared or t-test for means.
doi:10.1371/journal.pone.0049908.t001
Vascular Events after First Insulins
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e49908
glycaemic control, socioeconomic status and ethnicity were not
routinely available on all patients in this observational dataset in
the study years and recorded duration of diabetes has not been
validated. While these variables are likely to be non-differential
between the insulin types, we cannot exclude the presence of some
residual confounding. Confounding by indication should be
decreased as all subjects initiated insulin when they had poor
glycaemic control, although different insulins may be started in
different clinical circumstances such as ambulatory care versus in-
patient treatment. We chose to include all-cause mortality rather
than cardiovascular mortality because the recording of cause of
death has been shown to be incomplete in general practice
Table 2. Glucose-lowering therapy prescribed in the 112 days before starting insulin by insulin type and number of baseline oral
therapiesa (n (% of cohort)).
2 oral baseline treatments 3 oral baseline treatments
basal analogue pre-mix NPH basal analogue pre-mix NPH
Sulfonylurea 4 (0.4) 5 (0.5) 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)
Metformin+sulfonylurea 685 (66.3) 668 (62.8) 321 (72.8) 12 (3.0) 15 (4.5) 14 (8.8)
Metformin+thiazolidinedione 143 (13.8) 135 (12.7) 39 (8.8) 0 (0.0) 0 (0.0) 0 (0.0)
Metformin+ other 15 (1.5) 18 (1.7) 12 (2.7) 2 (0.5) 1 (0.3) 0 (0.0)
Sulfonylurea+thiazolidinedione 120 (11.6) 166 (15.6) 42 (9.5) 1 (0.3) 6 (1.8) 2 (1.3)
Sulfonylurea+other 9 (0.9) 13 (1.2) 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)
Thiazolidinedione+other 2 (0.2) 2 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Metformin+sulfonylurea+thiazolidinedione 47 (4.5) 37 (3.5) 14 (3.2) 309 (78.4) 239 (71.1) 83 (51.9)
Metformin+thiazolidinedione+other 4 (0.4) 4 (0.4) 0 (0.0) 17 (4.3) 6 (1.8) 5 (3.1)
Sulfonylurea+thiazolidinediones+other 1 (0.1) 2 (0.2) 0 (0.0) 12 (3.0) 6 (1.8) 1 (0.6)
Metformin+sulfonylurea+other 2 (0.2) 11 (1.0) 7 (1.6) 39 (9.9) 55 (16.4) 32 (20.0)
All groups 1 (0.1) 2 (0.2) 0 (0.0) 2 (0.5) 8 (2.4) 3 (1.9)
aThe counts include the OGLDs prescribed in the 112 days to index date, so the total number of baseline therapies may be greater than the number the people were
taking at baseline. The drug regimen at index date may have included more than one drug in the same category.
doi:10.1371/journal.pone.0049908.t002
Table 3. Comparison of incident macro- and micro-vascular disease between insulin treatment groups.
2 oral baseline treatments 3 oral baseline treatments
Endpoint
basal
analogue pre-mix NPH basal analogue pre-mix NPH
Macrovasculara
n (%) 51 (5.8) 117 (13.3) 42 (11.3) 19 (5.5) 26 (9.4) 13 (10.9)
Unadjusted HR (95% CI) Reference 1.41 (1.00 1.98) 1.18 (0.78 1.79) Reference 1.16 (0.64 2.11) 1.11 (0.54 2.29)
Adjusted HR (95% CI) b 1.08 (0.73 1.59) 1.00 (0.63 1.58) 0.97 (0.46 2.02) 0.77 (0.32 1.86)
Microvascularc
n (%) 100 (13.9) 133 (18.4) 68 (22.2) 33 (13.2) 42 (19.5) 31 (32.3)
Unadjusted HR (95% CI) Reference 0.93 (0.71 1.21) 1.12 (0.82 1.53) Reference 1.02 (0.64 1.62) 1.73 (1.05 2.84)
Adjusted HR (95% CI)b 0.79 (0.58 1.07) 1.03 (0.73 1.45) 1.05 (0.62 1.80) 1.87 (1.04 3.36)
Sensitivity analyses
Macrovascular + Angina
n (%) 42 (5.5) 123 (16.0) 39 (12.1) 23 (7.5) 28 (11.5) 13 (12.3)
Unadjusted HR (95% CI) Reference 1.93 (1.35 2.76) 1.41 (0.91 2.20) Reference 1.03 (0.59 1.80) 0.94 (0.47 1.89)
Adjusted HR (95% CI)b 1.49 (0.99 2.25) 1.23 (0.76 1.99) 0.76 (0.39 1.51) 0.75 (0.33 1.70)
Macrovascular+coronary revascularisation
n (%) 50 (5.8) 129 (15.2) 42 (11.6) 18 (5.4) 27 (10.0) 14 (12.3)
Unadjusted HR (95% CI) Reference 1.62 (1.16 2.27) 1.21 (0.80 1.83) Reference 1.33 (0.72 2.43) 1.41 (0.69 2.87)
Adjusted HR (95% CI)b 1.31 (0.89 1.91) 1.01 (0.64 1.59) 1.30 (0.63 2.68) 1.32 (0.56 3.14)
aComposite of all-cause mortality, MI, acute coronary syndrome or stroke.
bCovariates are described in the Methods text.
cComposite of neuropathy, nephropathy, and retinopathy.
doi:10.1371/journal.pone.0049908.t003
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databases [21] so non-cardiovascular events could not be reliably
excluded. HbA1c may have been measured more frequently in
those whose glycaemic control was poor resulting in higher mean
levels during follow-up than were actually the case. As all patients
should have levels measured after insulin introduction there should
be no difference between insulin types. The finding that the
number of patients who have a value measured remains relatively
consistent over time, across treatment groups, is also reassuring.
The first year of follow-up was excluded from all groups in the
analysis of vascular events as the distribution of insulin use in
terminally ill patients may not be even, causing bias, and any effect
of the choice of therapy on our outcomes is likely to be in the
medium- to long-term. The design was an intention-to-treat type
analysis so we did not censor follow-up at the next change of
glucose lowering treatment. As a result, the study did not
investigate the association of individual insulins and cardiovascular
outcomes but rather the mid-term consequences of one therapeu-
tic decision when starting insulin. Later changes in treatment
could be expected to relate to the efficacy and problems of the first
insulin regimen.
Overall, while the number of patients lost due to inclusion/
exclusion criteria appears high, the criteria for the initial data cut
were untypically wide due to the two stage identification process
(OGLD therapy and then insulin). For example, the requirement
for a year of data recording pre- and post-insulin resulted in the
removal of 29% of the total potential population but allowed time
for recording of information on prevalent events as well as
laboratory measurements. Many of those who had no baseline
HbA1c also had less than one year of data pre-insulin. Many of the
remaining exclusions occurred because the HbA1c could not be
interpreted rather than because it was not measured. The study
covered a time of HbA1c unit change in the UK.
In conclusion, in routine clinical practice no significant
difference in the rate of incident macrovascular disease was found
between first insulin type started during poor glycaemic control
over a period of 1 to 3.6 years. The increased risk of microvascular
disease between users of NPH and basal insulin was found in those
who escalated from three but not two agents and so warrants
further investigation. First time use of basal insulin was associated
with a smaller increase in weight gain and a smaller decrease in
HbA1c in the first year compared to other insulins in some
treatment groups. Glycaemic control was poor at baseline and,
while mean HbA1c decreased during insulin therapy, control
remained poor across all groups.
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